In August 2026, the AI computing power leasing market is experiencing a new wave of price hikes. The supply shortage of H200 chips has caused leasing prices to rise by 25% from the beginning of the ye...
On August 21, 2026, Eli Lilly released its Q3 2026 fiscal report, showing Zepbound revenue up 45% YoY, dividend raised for 9th consecutive year (8%), and accelerated AI drug R&D, making it a high-qual...
In the second half of 2026, the US AI computing market shows unprecedented growth. This article deeply analyzes the driving factors behind the continuous rise in AI computing demand, explores the stra...
At the end of the interest rate hiking cycle, the defensive value of dividend pharmaceutical stocks becomes prominent, while the proliferation of AI computing chips is driving pharmaceutical companies...
In the second half of 2026, the AI computing market continues to heat up, with major tech giants accelerating their layouts, computing rental prices soaring, and chip supply tightening. This article p...
On August 16, 2026, Meesho East released its Q3 earnings report, with revenue growing by 12% to $145 million, exceeding market expectations. Adjusted EPS reached $1.35, higher than expected. The compa...
On August 15, 2026, Microsoft announced a 20-year power purchase agreement with nuclear startup TerraPower to provide clean electricity for its AI data center. This move signals the resurgence of nucl...
In 2026, major US dividend-paying pharmaceutical giants are ramping up investments in AI technology to drive drug R&D and business transformation. This article analyzes how high-dividend pharma compan...
In 2026, US tech giants' capital expenditure in the AI field continues to rise, with companies like NVIDIA, Microsoft, and Google increasing investment to drive AI computing infrastructure constructio...
With breakthroughs in AI computing chip technology, US high-dividend pharmaceutical companies are accelerating their technological transformation by leveraging AI to enhance competitiveness in new dru...
In the second half of 2026, the AI compute market will undergo a major transformation. As inference demand takes over training demand to become the market driver, the widening supply gap of H200 chips...
In 2026, US pharmaceutical giants are reshaping drug development models through AI technology while maintaining stable dividend returns, achieving dual advantages of technological transformation and v...
This article provides an in-depth analysis of the latest dynamics in the US stock market's AI computing power sector in August 2026. From the latest technological breakthroughs by chip giants like NVI...
The Q2 2026 earnings season for US pharmaceutical giants has concluded, with multiple companies continuously increasing dividends, AI technology achieving breakthroughs in new drug development, and th...
With the rapid development of large language models like ChatGPT and Claude, the computing power competition among US tech giants has entered an intense stage. This article deeply analyzes the current...
